| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10907690 | Experimental Hematology | 2005 | 8 Pages |
Abstract
Our findings demonstrate that CD20Bi-armed ATC enhance cytotoxicity against CD20+ B-cell lines and circumvent complement-mediated rituximab resistance, providing a strong rationale for this immune-based strategy for the treatment of rituximab-refractory CD20+ B-cell malignancies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jonathan M. Gall, Pamela A. Davol, Ryan C. Grabert, Mark Deaver, Lawrence G. Lum,